Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disorder characterized by the progressive development and enlargement of fluid-filled cysts in the kidneys, accompanied by symptoms such as hypertension. The launch of Otsuka's Jynarque (tolvaptan), indicated for patients with rapidly progressive forms of the disease, changed the treatment paradigm, and this agent became the first and only disease-modifying therapy approved for ADPKD. Other therapies, such as antihypertensives, are also widely used in ADPKD patients. This longitudinal analysis of claims data provides detailed insight into U.S. prescribing patterns for ADPKD.
For the abstract please provide an overview paragraph here and then fill in the bulleted sections below. Feel free to modify the bulleted section. Leverage content from a brochure if you have one.
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key companies: Otsuka, Pfizer, Bausch Health, Merck, Novartis, GlaxoSmithKline’s Coreg CR and others
Key drugs: Jynarque (tolvaptan), ACE inhibitors, ARBs, calcium channel blockers, diuretics, beta-blockers
The Treatment Algorithms dashboard is an interactive supplement to our PowerPoint-based claims data analysis reports and retains the full set of analyses included in the reports (i.e., newly diagnosed patients, recently treated patients, persistency, and compliance). The dashboard allows for easier navigation of data visualizations and provides more detailed analyses examining the flow of treatment regimens in newly diagnosed and recently treated patients.